MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...